Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

102.50 +2.16 (+2.15%)
Official Closing Price Updated: 4:15 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
58 59 Next >
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
From Gilead Sciences, Inc.
Via Business Wire
Top 5 Health Care Stocks That Are Preparing To Pump In February
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
Via Benzinga
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
Preview: Gilead Sciences's Earnings
Via Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
Why Gilead Sciences Stock Dropped Today
Gilead missed revenue estimates with its latest quarter and issued underwhelming 2024 guidance. 
Via The Motley Fool
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
Wednesday is a bullish day on Wall Street, with major large-cap indices extending record highs, aided by robust corporate earnings. Despite the overall market optimism, concerns linger within segments... 
Via Benzinga
Topics Stocks
Exposures US Equities
Behind the Scenes of Gilead Sciences's Latest Options Trends
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today
Via Benzinga
2 Beaten-Down Dividend Stocks to Buy Hand Over Fist
These stocks aren't value traps. 
Via The Motley Fool
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
The Dow gained +141 points, +0.37%, while the S&P gained +0.23%. The Nasdaq, while positive, was essentially flat at +0.07%, while the small-cap Russell won the day, +0.85%, and continues inching its... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Gilead Sciences Stock Is Trading Lower After The Bell
Gilead Sciences shares are trading lower in Tuesday's after-hours session after the company reported weak earnings results and issued soft guidance. 
Via Benzinga
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Gilead Rode An Unexpected Source For Its Sales Beat, But Profit Came Up Short
Gilead reported slightly better-than-expected fourth-quarter sales, while earnings and profit guidance lagged. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?
At noon trading in New York, major equity indices on Wall Street remain directionless as traders evaluate the future course of monetary policy ahead of several speeches by Federal Reserve officials in... 
Via Benzinga
Topics Economy
Exposures Interest Rates
3 Top Pharma Stocks to Buy Now: February 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth. 
Via InvestorPlace
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
From Gilead Sciences, Inc.
Via Business Wire
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is. 
Via Benzinga
Exposures COVID-19
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy. 
Via Benzinga
Gilead and Arcus Announce Amended Collaboration and Equity Investment
From Arcus Biosciences
Via Business Wire
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments. 
Via Benzinga
Despite its impressive fundamentals, NASDAQ:GILD remains undervalued.
When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list. 
Via Benzinga
Exposures Product Safety
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.